{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"14.6","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Complete and Partial Tumor Response by RECIST 1.0. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","dispersionType":"90% Confidence Interval","groups":[{"description":"Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)","id":"OG000","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"CT scan or MRI if used to follow lesion(s) for measurable disease every other cycle for the first 6 mnths; then every 3 mnths thereafter until dx progression is confirmed; also repeat any other time clinically indicated, assessed up to 6 months.","title":"Objective Tumor Response (Complete or Partial)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}